Drugs / Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes
Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02661282 | Jun 2016 → Feb 2022 | cytomegalovirus infection, gliosarcoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02661282 ↗ |
| Modality | Cell therapy | “Autologous CMV-specific cytotoxic T cells may stimulate the immune system to attack specific tumor cells and stop them from growing or kill them.” NCT02661282 ↗ |
| Route | Intravenous | “Given IV” NCT02661282 ↗ |